It is well-known that germline mutations in homologous recombination genes, for example BRCA1/2, predispose individuals to breast and ovarian cancer, and that these mutations are synthetic lethal with poly(ADP-ribose) polymerase (PARP) inhibition [213,214]. This evidence concerns the gene PARP1 and ovarian cancer.